CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.

导出原文传递

翻译打印收藏纠错

作者： Mark H,O'Hara ^[1] ; Eileen M,O'Reilly ^[2] ; Gauri,Varadhachary ^[3] ; Robert A,Wolff ^[3] ; Zev A,Wainberg ^[4] ; Andrew H,Ko ^[5] ; George,Fisher ^[6] ; Osama,Rahma ^[7] ; Jaclyn P,Lyman ^[8] ; Christopher R,Cabanski ^[8] ; Rosemarie,Mick ^[1] ; Pier Federico,Gherardini ^[8] ; Lacey J,Kitch ^[8] ; Jingying,Xu ^[8] ; Theresa,Samuel ^[8] ; Joyson,Karakunnel ^[8] ; Justin,Fairchild ^[8] ; Samantha,Bucktrout ^[8] ; Theresa M,LaVallee ^[8] ; Cheryl,Selinsky ^[8] ; Jacob E,Till ^[1] ; Erica L,Carpenter ^[1] ; Cécile,Alanio ^[9] ; Katelyn T,Byrne ^[10] ; Richard O,Chen ^[11] ; Ovid C,Trifan ^[12] ; Ute,Dugan ^[13] ; Christine,Horak ^[13] ; Vanessa M,Hubbard-Lucey ^[14] ; E John,Wherry ^[15] ; Ramy,Ibrahim ^[8] ; Robert H,Vonderheide ^[16]

作者单位： Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ^[1] Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[2] Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA. ^[3] Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. ^[4] Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. ^[5] Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. ^[6] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ^[7] Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. ^[8] Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ^[9] Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ^[10] Personalis, Menlo Park, CA, USA. ^[11] Apexigen, San Carlos, CA, USA. ^[12] Bristol Myers Squibb, New York, NY, USA. ^[13] Cancer Research Institute, New York, NY, USA. ^[14] Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ^[15] Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: rhv@upenn.edu. ^[16]